Biotech "Tweets of the Week" for May 26-31, 2015#ASCO15 festivities, Part One
Featuring: $FOLD $BLUE $SRPT $QURE $BMY $FPRX $KITE $GBIM $RTRX $CLLS $ATNM $PBYI $AMRN $FMI $ONTY $IMGN $TGTX $CLDX $XBI $IBB Check out the Biotech Tweets of the Week archive. |
|
So when is everyone headed out to #ASCO15?
— Meg Tirrell (@megtirrell) May 26, 2015
$CERU CRLX101 Receives Orphan Drug Designation For The Treatment Of Ovarian Cancer.
— Bio Stocks™ (@BioStocks) May 26, 2015
$AEGR - no data provided, but met primary endpoint in their Japanese pIII. Will file late 2015/early 2016. http://t.co/xGKiclTpyi
— Brad Loncar (@bradloncar) May 26, 2015
Amicus Tx $FOLD on track to submit for European approval in 2Q, and accelerated assessment shrinks review period by 60 days to 150
— Dan Budwick (@DanBudwick) May 26, 2015
#ProTip Good bios rarely break EMA50d after good data. $BLUE types not even EMA20d ;)
— Ponty (@pbmech) May 26, 2015
$afmd Amphivena has selected a lead therapeutic candidate, named AMV-564, to advance into clinical development for the treatment of AML.
— Joe Librescu (@techwhitepapers) May 26, 2015
There are great technical traders in Twitterville, but to succeed in the #biotech you have to know when to use & stop using technicals $SRPT
— Joe (@GantosJ) May 26, 2015
$QURE the partnership with $BMY is now official. In other words $BMY paying $100m in near-term to $QURE. And paying $33.84/share for stock
— Shane Blackmon (@shaneblackmon) May 26, 2015
Oppy. view $PTCT as very-attractive at current valuation given upside/ downside,Upside to $155 price target exists,Takeout premium not incl.
— Tom Silver (@TomSilver39) May 26, 2015
$BLUE and $FPRX enter into license agreement for novel antibodies to develop CART therapy.
— Brad Loncar (@bradloncar) May 26, 2015
$BLUE Management putting on a #clinic as to how to build the next $CELG $GILD. #epic
— 23Chromz (@23Chromz) May 26, 2015
@23aloha although $KITE is still my largest CAR-T play. But this is good news too, $FPRX has more broad pipeline.
— Adam Singer (@AdamSinger) May 26, 2015
@maverickny @3nt That's definitely a collectible. I think Dr. Allison might be the coolest guy in cancer research.
— Brad Loncar (@bradloncar) May 26, 2015
The podcast renaissance is taking biotech by storm. http://t.co/AMApORMV92 by @3NT & @MaverickNY joins Fierce Biotech Radio and RAREcast.
— Ethan O. Perlstein (@eperlste) May 27, 2015
Doesn't market already "discount" cancer drugs by not using those less effective? ie Tarceva in pancreatic. $ESRX plan seems weak.
— Adam Feuerstein (@adamfeuerstein) May 27, 2015
$GBIM #HBV Ph2 #FAIL
http://t.co/lySrgVdTAh
— Andy Biotech (@AndyBiotech) May 27, 2015
$GBIM ph2 results - weak signs of activity in virally suppressed patients but not Stat sig - this was always a high-risk trial
— Red Acre Investments (@redacre) May 27, 2015
$JUNO pays Editas $25M upfront and up to $22M in research support over the next 5 years. Plus up to $230M in biobucks for each of 3 programs
— Brad Loncar (@bradloncar) May 27, 2015
So if editas were public it would be up > $1.5 billion based on $fprx trading.
— NathanAaron (@NathanAhron) May 27, 2015
$RTRX To Sell Priority Review Voucher To $SNY
— Bio Stocks™ (@BioStocks) May 27, 2015
$rtrx lol Martin told u to buy some
— V (@vigkap) May 27, 2015
$CLLS allogeneic CAR T cells may “ultimately provide an off-the-shelf solution” and economies of scale, Cowen says in note ahead of #ASCO15
— Sasha Damouni (@SashaDamouni) May 27, 2015
It's interesting how much volume there was on $GBIM yesterday, out of nowhere, and then they press release today...
— Joe Prete, Pharm.D. (@JoeP450) May 27, 2015
Cancer immunotherapy stocks are rallying into #ASCO15 just like for #AACR15. But will they sell off after as well? pic.twitter.com/EeCVQ72yBX
— Brad Loncar (@bradloncar) May 28, 2015
$ZGNX Nice move... Zogenix announces new efficacy data from a long-term study of low-dose Fenfluramine for treatment of Dravet Syndrome
— BioBreakout (@BioBreakout) May 27, 2015
$SRPT #Dadvocates pic.twitter.com/sdSGgmNiD9
— jenn mcnary (@jennmcnary) May 27, 2015
@FajaJake great long term stock. short term with ipo lockup expiry still in progress who the hell knows.
— william keough (@2015Stalog17) May 27, 2015
If anyone is wondering why bios are boosting for absolutely no reason its because I went inverse a handle ago.. Your welcome
— Keith Stocks (@KeithStokes14) May 27, 2015
$JUNO & $KITE red today on a very green biotech day w/ $IBB up 1.35%
— Sheff (@SheffStation) May 27, 2015
$ALDR $RARE new all time highs today.
— BioBounce.com (@BioBounce) May 27, 2015
$DCTH up ~100% on some fluffy PR for a forum that they organized with quotes from doctors they paid…This week is officially getting insane…
— Andy Biotech (@AndyBiotech) May 27, 2015
. @ErikNeelsen The history of radio-labeled antibodies: Great clinical data, approvals, near-zero sales. Why is $ATNM different?
— Adam Feuerstein (@adamfeuerstein) May 27, 2015
$AMRN so excited for their NCE judgement - they sent me the press release twice
— Red Acre Investments (@redacre) May 28, 2015
$PBYI Puma Bio Restricting Access to Breast Cancer Event at ASCO 2015 http://t.co/dIs2RBqpTP via @TheStreet
— BioBreakout (@BioBreakout) May 28, 2015
$AMRN so excited for their NCE judgement - they sent me the press release twice
— Red Acre Investments (@redacre) May 28, 2015
noone cared for $CLLS headline mid april " Cellectis granted intellectual property rights for CRISPR technology " looks like $PFE did
— Captain Sequence (@CaptainFuture__) May 28, 2015
$FMI will be presenting its PatientMatch software at #ASCO15 - kinda like a social network for cancer tumors.
http://t.co/YVZSduij5z
— Caroline Chen (@CarolineYLChen) May 28, 2015
General rule of thumb: If a biotech company has the data & won't disclose it, the data sucks. If good, would be shouting from roof tops
— John Welsh (@johnwelshtrades) May 29, 2015
who knew there was $10B in $BMY clinical data risk today....anyone, Bueller, anyone?
— Don Shimoda (@zDonShimoda) May 29, 2015
#ASCO15 $ONTY $ARRY ONT-380
http://t.co/SnlNDsU0W7
Brain mets data looking great even w/ bigger N:
1CR + 4PR + 9SD in ALL 14 evaluable pts
— Andy Biotech (@AndyBiotech) May 30, 2015
$ONTY data including brain mets exceeds my expectations. Very impressive.
— avidresearch (@avidresearch) May 30, 2015
As of close on Friday:
$ONTY 350M MC
$PBYI 6.3B MC
— 23aloha (@23aloha) May 30, 2015
If #ASCO15 is all about checkpoints, #ASCO17 will be all about checkpoint/vaccine combos.
— David Miller (@AlpineBV_Miller) May 30, 2015
$ONTY and $IMGN having good #ASCO15 Saturday.
— Adam Feuerstein (@adamfeuerstein) May 30, 2015
When you reach over 100% in your options, don't get greedy, take off your money & keep riding the trend with FREE® calls to reduce risk $BMY
— Joe (@GantosJ) May 30, 2015
ASCO Annual Meeting: Record attendance of over 35,000 total attendees... Hearing the latest cancer science. #ASCO15 pic.twitter.com/VIFoRGjY0X
— Kristin Ludwig (@LuddyK) May 30, 2015
One day $CLDX may just convince me that cancer vaccines can work. It's got to happen, eventually. #ASCO15
— John Carroll (@JohnCFierce) May 30, 2015
Arrived in CNS/GBM session to see breaking news that Beau Biden died of brain cancer. Wow so young. http://t.co/mS8XsTqtCX #ASCO15
— Sally Church (@MaverickNY) May 31, 2015
@MudsharkOX $TGTX SAFETY SAFETY SAFETY clearly distinguishing itself going forward IMHO LONGTERM horizon Marketcap going up
— dougheuring (@dougheuringaria) May 31, 2015
Most physicians think they are impartial, Jagsi warns that's magical thinking #ASCO15 pic.twitter.com/9WKFXt69Rh
— Mary Jo Laffler (@PinkSheetMaryJo) May 31, 2015
#ASCO15's big winner this year = periscope. Clearly gonna take social media in a very special direction. @adamfeuerstein @megtirrell
— Brad Loncar (@bradloncar) May 31, 2015
The Monday after ASCO: when everything you think should happen to your favorite oncology ticker, doesn't.
— BioBounce.com (@BioBounce) May 31, 2015
Allison: "Ignore the tumor, just work the immune system." Hard to emphasize how revolutionary that concept was (is).
#ASCO15
— David Miller (@AlpineBV_Miller) May 31, 2015
$CLDX presents great cancer vax data in GBM, $NWBO doesn't but over-compensates w/ ludicrously $$$$ booth. #ASCO15 pic.twitter.com/aLUBIIfxiI
— Adam Feuerstein (@adamfeuerstein) May 31, 2015
Another note regarding $tril I confirmed that tril will start attending conferences for Cowen and Leerink which will increase exposure
— Joshua B (@srqstockpicker) June 1, 2015
Bear raids on winners $ONTY $CTIC $CLDX leading up to #ASCO15 Bull runs in $CLDN $AERI leading up to #fail data #WallStreetPlaybook $STUDY
— S Manian (@DrSManian) June 1, 2015
Len Saltz just blew up #ASCO15 by pointing out that cancer drugs cost way way too much. Which they do.
— Matthew Herper (@matthewherper) May 31, 2015